Enhanced Composition for Promoting FGF21 Secretion

This inventive concept discloses improved compositions and methods for promoting the secretion of fibroblast growth factor 21 (FGF21), addressing the limitations of the original patent by enhancing efficacy, reducing dosage, and providing real-time monitoring.

The original patent relates to a composition for promoting the secretion of FGF21, but it has inherent limitations, such as variable efficacy and potential high dosages. The present inventive concept solves these problems by introducing novel combinations of Bifidobacterium bacterium with prebiotics, probiotics, or nutrients, and by developing sustained-release formulations and real-time monitoring systems.

The inventive concept comprises four main aspects: (1) a system combining Bifidobacterium bacterium with a prebiotic to enhance growth and FGF21 secretion; (2) a method of enhancing efficacy by co-administering the composition with a probiotic; (3) a composition comprising Bifidobacterium bacterium and a nutrient to enhance FGF21 gene expression; and (4) a sustained-release formulation and real-time monitoring system to reduce dosage and optimize treatment. These innovations address the limitations of the original patent and provide more efficient and effective solutions.

The new claims introduce novel combinations of components and methods that are not obvious from the original patent. The use of prebiotics, probiotics, and nutrients to enhance FGF21 secretion, as well as the development of sustained-release formulations and real-time monitoring systems, constitutes a significant inventive step beyond the original patent.

Alternative embodiments of the inventive concept could include different types of prebiotics, probiotics, or nutrients, as well as varying formulations and delivery methods. Additionally, the inventive concept could be adapted for use in different applications, such as food products or pharmaceuticals.

The inventive concept has significant commercial potential in the fields of nutrition, pharmaceuticals, and healthcare, particularly in the development of treatments for metabolic disorders and other conditions related to FGF21 secretion.